AC
VRTX icon

Arjuna Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Arjuna Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,978
Closed -$1.17M – 125
2025
Q3 		$1.17M Sell
2,978
-132
-4% -$55.2K 0.29% 81
2025
Q2 		$1.38M Sell
3,110
-890
-22% -$410K 0.37% 65
2025
Q1 		$1.94M Sell
4,000
-1,541
-28% -$718K 0.54% 47
2024
Q4 		$2.23M Buy
5,541
+68
+1% +$31.5K 0.59% 46
2024
Q3 		$2.55M Sell
5,473
-534
-9% -$257K 0.66% 47
2024
Q2 		$2.82M Buy
6,007
+50
+0.8% +$21.7K 0.76% 40
2024
Q1 		$2.49M Buy
5,957
+1,339
+29% +$566K 0.71% 42
2023
Q4 		$1.88M Buy
4,618
+243
+6% +$89.8K 0.59% 51
2023
Q3 		$1.52M Buy
4,375
+29
+0.7% +$10.1K 0.55% 56
2023
Q2 		$1.53M Sell
4,346
-22
-0.5% -$7.41K 0.54% 54
2023
Q1 		$1.38M Sell
4,368
-3,069
-41% -$920K 0.54% 53
2022
Q4 		$2.15M Buy
7,437
+243
+3% +$74.1K 0.99% 34
2022
Q3 		$2.08M Buy
+7,194
New +$2.07M 1.02% 29
2020
Q4 		– Sell
-4,151
Closed -$1.13M – 102
2020
Q3 		$1.13M Buy
4,151
+55
+1% +$15.2K 0.7% 45
2020
Q2 		$1.19M Buy
+4,096
New +$1.11M 0.82% 43
2019
Q3 		– Sell
-2,218
Closed -$406K – 95
2019
Q2 		$406K Buy
2,218
+258
+13% +$45.1K 0.29% 76
2019
Q1 		$361K Buy
1,960
+141
+8% +$26K 0.28% 79
2018
Q4 		$302K Buy
1,819
+12
+0.7% +$2.08K 0.28% 80
2018
Q3 		$349K Sell
1,807
-4
-0.2% -$712 0.26% 82
2018
Q2 		$308K Buy
+1,811
New +$281K 0.25% 81

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Arjuna Capital's VRTX Position: Q4 2025 in Review

Arjuna Capital sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 2,978 shares — an estimated $1.17M sold.

Arjuna Capital first reported a position in VRTX in Q2 2018 and held it in 20 quarters. The position peaked at $2.82M in Q2 2024. 1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Arjuna Capital reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Arjuna Capital sold 2,978 Vertex Pharmaceuticals shares in Q4 2025, an estimated $1.17M.
  • Arjuna Capital first reported a position in Vertex Pharmaceuticals in Q2 2018 and held it in 20 quarters.
  • Arjuna Capital's Vertex Pharmaceuticals position peaked at $2.82M in Q2 2024.
  • 1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Arjuna Capital's 13F filing for Q4 2025, filed 5 Feb 2026.